Joshua Rokach, a professor in Florida Tech’s Department of Biomedical and Chemical Engineering and Sciences who has drawn worldwide recognition for achieving the first syntheses of major inflammatory mediators such as leukotrienes and lipoxins that are responsible for asthma and rhinitis, has been named a Fellow of the National Academy of Inventors (NAI), the organization recently announced.
Rokach, a chemist who has been at Florida Tech since 1989, joins a 2018 class of 147 renowned academic inventors from top universities and research agencies worldwide, including CalTech, M.I.T., Harvard University, Georgia Tech and Oak Ridge National Laboratory.
The 2018 class of Fellows represent 125 research universities and governmental and non-profit research institutes worldwide and are named inventors on nearly 4,000 issued U.S. patents.
Rokach has 119 patents in the U.S. and internationally. Among them are three patents jointly owned by Florida Tech and McGill University that in July 2018 were licensed to Fairhaven Pharmaceuticals, a Canadian-based start-up company that plans to bring the 5-OXO-ETE receptor antagonist compounds that Rokach developed at Florida Tech into human clinical trials.
Election to NAI Fellow status is the highest professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society.
The full news release can be found here.